Zelenoleucel is a cell therapy commercialized by Marker Therapeutics, with a leading Phase II program in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). According to Globaldata, it is involved in 4 clinical trials, of which 1 was completed, and 3 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Zelenoleucel’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Zelenoleucel is expected to reach an annual total of $42 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
zelenoleucel (MT-401) is under development for the treatment of acute myelocytic leukemia, relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, sarcoma, breast cancer, pancreatic cancer, lymphoma, ovarian cancer. The therapeutic candidate is administered as intravenous infusion. The cellular immunotherapy constitutes donor derived multi tumor associated antigen (TAA)-specific T cells which act by targeting cancer cells which express WT1, PRAME, NY-ESO-1, Survivin tumor associated antigens. It is administered as an intravenous infusion.
Marker Therapeutics Overview
Marker Therapeutics is a clinical-stage immuno-oncology company that carries out the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company’s pipeline products include MT-401, which is used for the treatment of post-transplant AML and MT-601, which is used for the treatment of advanced unresectable pancreatic cancer. It also provides Multi-Antigen Targeted (MultiTAA) technology that utilizes a novel, non-genetically modified cell therapy approach that selectively expands tumor-specific T cells from a patient’s blood. Marker Therapeutics carries out several clinical studies including acute myeloid leukemia, non-Hodgkin’s lymphoma, multiple myeloma and breast cancer. Marker Therapeutics is headquartered in Houston, Texas, the US.
The company reported revenues of (US Dollars) US$1.2 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$0.5 million in FY2020. The operating loss of the company was US$41.9 million in FY2021, compared to an operating loss of US$28.9 million in FY2020. The net loss of the company was US$41.9 million in FY2021, compared to a net loss of US$28.7 million in FY2020. The company reported revenues of US$4 million for the third quarter ended September 2022, compared to a revenue of US$0.8 million the previous quarter.
For a complete picture of Zelenoleucel’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.